^
Association details:
| Biomarker: | NCOA4-RET fusion |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | FHND5071 (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LB330 / 21 - FHND5071: a selective RET inhibitor with unique pharmacokinetic profile
Published date:
03/15/2023
Excerpt:
In tumor models, FHND5071 exhibited significant anti-tumor efficacy in Ba/F3 KIF5B-RET model…30 mg/kg FHND5071 (QD) demonstrated significant anti-tumor efficacy with 100% TGI in patient-derived xenograft models (colorectal cancer with CCDC6-RET and ovarian cancer with NCOA4-RET). In CCDC6-RET intracranial xenograft model, 30 mg/kg FHND5071 (QD) significant prolonged life time of model mice.
